Among the 443 clinical isolates of Escherichia coli and Klebsiella spp. collected between June and November 2003 from 3 university hospitals in Korea, 62 isolates were confirmed as extended-spectrum beta-lactamase (ESBL)- or plasmid-mediated AmpC beta-lactamase-producers by double disk synergy test, PCR and sequencing for beta-lactamase genes. The most frequently identified ESBL gene among E. coli and K. pneumoniae isolates was bla(SHV-12) and bla(CTX-M) (bla(CTX-M-9), bla(CTX-M-14), bla(CTX-M-3), and bla(CTX-M-15)). Four kinds of plasmid-mediated AmpC beta-lactamases, ACT-1, CMY-1, CMY-2, and DHA-1, were detected. ESBL production was associated with high levels of resistance to tetracycline, sulfisoxazole, streptomycin, kanamycin, gentamicin and tobramycin when compared to non-ESBL producing isolates. Conclusively, this study suggests that the CTX-M beta-lactamases are prevalent and various kinds of plasmid-mediated AmpC enzymes are distributed in clinical isolates of E. coli and Klebsiella spp. in Korea.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: